The hypothalamic supraoptic nucleus (SON) contains cell bodies of magnocellular neurons that synthetize and release neurohypophyseal hormones such as vasopressin and oxytocin. Immunohistochemical studies have demon strated that terminals of cholinergic neurons exist in the SON (1, 2) . We have previously demonstrated that cholinergic agonists microinjected into the SON induced antidiuresis by stimulating vasopressin secretion, through the activation of muscarinic receptors in the nucleus (3, 4) , suggesting that cholinergic neurons in the SON have an important role in the regulation of vasopressin secre tion.
Microdialysis is a technique introduced by Ungerstedt et al. (5, 6) , which measures the in vivo release of neuro transmitters from brain tissue. Recently, acetylcholine (ACh) has been measured by high pressure liquid chro matography (HPLC) connected with the microdialysis sys tem (7) . This method provides in vivo information on the cholinergic system of the brain. By using the in vivo microdialysis method, the ACh release has determined in the hippocampus (8) , striatum (9-11) and cortex (12, 13) . These studies have indicated that presynaptic autorecep tors exist on cholinergic neuronal terminals and inhibit the ACh release.
Muscarinic receptors are pharmacologically divided into three subtypes, M1, M2 and M3 (14, 15) . The muscar inic autoreceptors involved in the regulation of the ACh release are suggested to be of the M,-, M2 or M3-subtype in the individual regions (16) (17) (18) (19) . Such autoreceptors have never been reported in the hypothalamus. In the present study, we measured the spontaneous release of ACh in the SON using the HPLC-brain microdialysis method to study the role of ACh in the nucleus. It was also our aim to determine the muscarinic receptor subtype involved in the autoregulation of ACh release.
MATERIALS AND METHODS

Animals and drugs
Male Wistar rats (weighing 280-320 g) were used. The rats were maintained in a light-controlled environment with food and water given ad libitum. Atropine sulfate, pirenzepine dihydrochloride, oxotremorine sesquifuma rate, physostigmine salicylate and tetrodotoxin (TTX) were purchased from Sigma Chemical Co. (St. Louis, MO, USA).
Microdialysis procedure
Rats were anesthetized with sodium pentobarbital (40 mg/kg, i.p.) and immobilized in a stereotaxic instrument (Takahashi, Co., Tokyo) for implantation of a guide can nula for the microdialysis probe. The skull was then ex posed and a burr hole was drilled to insert the guide can nula (G-12, Eikom, Kyoto) into the SON (A, 6.28; L, 1.3; H, 7.8 in mm) according to the atlas of Konig and Klippel (20) . The guide cannula was secured in place with dental cement. After a recovery period of one day, a microdialy sis probe (BDP-I-12-02, Eicom) was inserted through the guide cannula to a depth 8.8 mm into the SON. The loca tion of the probe was confirmed by visual examination of the brain at the end of each experiment. One end of the di alysis probe was connected to the infusion pump (EP-50, Eikom), and the other end was attached to the sample loop of the automated sample injector (model AS-10, Ei com) by means of polyethylene tubing. The dialysis probe was continuously perfused at a flow rate of 2 pl/min with saline containing 10-4 M physostigmine, and a sample of the dialysate was collected every 20 min in the sample loop of the automated sample injector, which was con nected to an HPLC system.
HPLC analysis of ACh
ACh in the dialysate was measured by HPLC combined with an enzyme-immobilized column and an electro chemical detector according to the method of Damsma et al. (21) . For separation of ACh, an Eicompak AC-Gel column (6 x 150 mm, Eicom) was used. An AC-Enzyme pak column (ACh esterase and choline oxidase-immobi lized, Eicom) was used to convert ACh and choline to hydrogen peroxide, which was detected by an electro chemical detector with a platinum electrode (ECD-100, Eicom) at 450 mV. The mobile phase was delivered by a pump (EP-10, Eicom) at 1.0 ml/min and contained 0.1 M sodium phosphate buffer (pH 8.0), 300 mg/l sodium 1 decanesulfonate, and 65 mg/l tetramethylammonium chloride. Quantification of collected ACh was performed by comparison with the peak height of authentic standard (ethylhomocholine, EHC).
In vitro recovery experiments
Before experiments of in vivo microdialysis, we deter mined the recovery of ACh through the dialysis mem brane. The probe was placed in saline containing ACh (3 x lo-'and 10-6 M) and was perfused with saline-physo stigmine solution at 2 p1/min. The concentrations of ACh in the dialysate collected for 20 min were analyzed and compared with the concentrations outside the dialysis tube. The recovery of ACh was 9.8 ± 1.4 and 9.7 ± 1.6'o at 3 x 10' and 10-6 M, respectively (n=5). The data in the present study were expressed without the correction for recovery. Differences were considered significant at P < 0.05 .
The ED50 values for atropine and pirenzepine were cal culated from the dose-effect curves, drawn by the least squares method. Effects of muscarinic antagonists on the ACh release When 10-'M atropine was continuously infused into the SON for 120 min, the ACh release was markedly in creased, reaching the maximal level (257±28% of the ini tial control, n=10) at 20-40 min after the infusion (Fig.  3) . The atropine-induced ACh release was not significant at 100-120 min after the infusion even in the presence of this antagonist, suggesting a possibility that desensitiza tion may occur during the infusion of the antagonist. Figure 4 shows the effect of pirenzepine (10-3 M) on the ACh release. Pirenzepine also increased the ACh release to 198 ± 38% (n = 8) of the initial control at 20 40 min af ter the infusion. The desensitization also occurred in the case of pirenzepine. Figure 5 demonstrates the dose-effect curves for the stimulatory effects of atropine and pirenzepine on the ACh release. Atropine (10-8-10-5 M) increased the ACh release in a dose-dependent manner. The maximal effect was achieved when 10-6 M atropine was used. Pirenze pine also increased the ACh release in a dose-dependent manner. The ED50 was 9.4 (3.2-27.5) x 10-8 M for atro pine and approx. 10-4 M for pirenzepine.
Effect of oxotremorine on the basal and atropine-induced A Ch release
Infusions of the muscarinic agonist oxotremorine (10-6 and 10-5 M) significantly decreased the basal ACh release (72±8 and 72±701o at 10-6 and 10-5M, respectively: Fig. 6 ). The effect of simultaneous infusion of oxotremo rine and atropine was then determined. The stimulation of ACh release (256 ± 26%, n = 5) induced by 10-6 M atro pine was significantly inhibited by the simultaneous infu sion of 10-5 M oxotremorine (157±1501o, n=5), but not by 10-6M oxotremorine (231±3601o, n=5). 
DISCUSSION
The present study using an in vivo microdialysis method clearly demonstrated that ACh was released spon taneously in the SON. We have previously shown that cholinergic agonists or physostigmine microinjected into the SON induced antidiuresis by stimulating vasopressin secretion through the activation of muscarinic receptors (3, 4) . Therefore, the demonstration of ACh release in the SON-dialysate suggests that endogenous ACh has some regulatory role in the nucleus. In this study, the value of the basal ACh release in the SON was 5 50 fmol/ pcl. This value was not higher than that of the striatum (180 fmol/pl), but was similar to that of cortex (47 fmol/pl) or hippocampus (76 fmol/pl) (12) . It was supposed that the basal ACh release decreased by the addition of TTX (10-6 M) in a time-dependent manner, although the difference between the value of the basal ACh release at 20-40 min and that at 60-80 min after the addition was not sig nificant. The finding indicates that the basal ACh release in the SON-dialysate originates predominantly from cholinergic neurons.
Muscarinic receptor antagonists, atropine and pirenze pine, increased the ACh release from the SON and the atropine-induced ACh release was inhibited by a muscar inic receptor agonist oxotremorine. Oxotremorine alone caused a significant decrease in the basal ACh release. These results are consistent with the previous reports on the rat cortical brain slices (22) , striatal slices (23, 24) , and isolated nerve endings from various regions of brain (25) (26) (27) . Although only the effect of oxotremorine on the basal ACh release was tested in this study, it is necessary to study whether similar effects are also evoked by the other muscarinic agonist. The spontaneous release of ACh from central cholinergic neurons is regulated by presynaptic autoreceptors. The released ACh interacts with presynaptic muscarinic receptors to inhibit the fur ther release of the neurotransmitter (28) . Therefore, our results suggest that autoreceptors which are involved in the regulation of the ACh release exist in the terminals of cholinergic neurons in the SON, as already demonstrated in the striatum (17) and hippocampus (8) . Although the effect of oxotremorine on the basal ACh release was unex pectedly less potent (approx. 18% decrease), it is likely that the basal ACh release has been mostly inhibited by en dogenous ACh since the microdialysis was carried out in the presence of 10-4 M physostigmine (24) .
The finding that the stimulation of ACh release induced by atropine or pirenzepine decreased during the infusion of the antagonist (Figs. 3 and 4) suggested an occurrence of desensitization. The desensitization was observed with 10-6-10-5 M atropine and 10-'M pirenzepine. Such a desensitization was not found in the striatum (9) or hip pocampus (19) . The desensitization may reflect a change in the muscarinic receptor regulating the ACh release. Fur ther studies are needed to investigate this hypothesis.
There are multiple subtypes of muscarinic receptors. One subtype with high affinity for pirenzepine is termed M1 and another with lower affinity, M2 or non-M1 (14) . At present, the M,, M2 and M3 subtypes have been pharma cologically identified, and these are highly distributed in the forebrain, heart and glands, respectively (29) . Recent molecular biological studies indicated the existence of five genes (m1-m5) encoding muscarinic receptors (30, 31) . Several studies have attempted to characterize the subtype of muscarinic autoreceptor involved in the regulation of the ACh release, using different preparations. Marchi and Reiteri (32), working with synaptosomes, found that the M2-subtype regulates the ACh release and is located on nerve terminals in the hippocampus and the cortex. Ono et al. (26) used muscarinic receptor agonists to study the ACh release from hippocampal synaptosomes and con cluded that the M2-subtype rather than the M, regulates the ACh release. The M2-subtype also regulates the ACh release from striatal slices (23, 33) . In contrast, Suzuki et al. (22) concluded that the M1-subtype modulates the ACh release in rat basal forebrain slices. In vivo microdialysis studies by Consolo et al. (16, 34) and De Boer et al. (17) demonstrated that the M3-subtype rather than M2 was involved in the regulation of the ACh release in the striatum.
Our results demonstrated that the M1-receptor-selective antagonist pirenzepine had a 1000 times less potent effect on the ACh release than the non-selective antagonist atro pine. Therefore, the non-M, type of receptor may func tion predominantly as presynaptic autoreceptors in the regulation of ACh release in the SON. The inhibition of the basal ACh release by oxotremorine which exhibits a much higher affinity for M2-subtype than M1 (35) suggests that the non-M1 type may be the M2-subtype, as reported previously (16, 17, 23, 26, (32) (33) (34) . To further character ize the muscarinic autoreceptor subtype in the SON, fur ther investigations with the use of M2 and M3-receptor selective antagonists are needed.
In conclusion, the present study showed a negative feed back regulation of the spontaneous ACh release through muscarinic autoreceptors in the SON. The weak effect of pirenzepine in increasing the ACh release, compared with atropine, suggests that non-M1-muscarinic receptor sub type mainly regulates the ACh release in the nucleus. Therefore, ACh in the SON may play an important role in stimulation of vasopressin secretion through a post synaptic muscarinic receptor (subtype is unknown), the re lease of which is regulated by a presynaptic non-M1-sub type receptor.
